Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Tripeptides – e.g. – tripeptide thyroliberin – etc.
Patent
1996-08-21
1998-07-14
Tsang, Cecilia J.
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Tripeptides, e.g., tripeptide thyroliberin , etc.
514 19, 514 18, A61K 3806
Patent
active
057805903
ABSTRACT:
The invention is directed to a non-hygroscopic stable crystalline form of the antithrombotic compound -cyclohexyl-alanine amide, to processes for preparing said stable crystalline form, to a pharmaceutical composition thereof, and intermediates thereof, and the invention is directed also to processes for preparing a compound of the formula ##STR1## wherein: A, B, Z, E.sup.1, E.sup.2, G, R, m, n, and p are as defined herein.
REFERENCES:
patent: 3821188 (1974-06-01), McKinley et al.
patent: 4683291 (1987-07-01), Zimmerman et al.
patent: 4857508 (1989-08-01), Adams et al.
patent: 4879313 (1989-11-01), Tjoeng et al.
patent: 4910190 (1990-03-01), Bergeson et al.
patent: 4952562 (1990-08-01), Klein et al.
patent: 4992463 (1991-02-01), Tjoeng et al.
patent: 5023233 (1991-06-01), Nutt et al.
patent: 5037808 (1991-08-01), Tjoeng et al.
patent: 5051405 (1991-09-01), Klein et al.
patent: 5053392 (1991-10-01), Klein et al.
patent: 5064814 (1991-11-01), Klein et al.
patent: 5086069 (1992-02-01), Klein et al.
Spatola, Peptide Backbone Modifications, Chem.&Biochem.ofAmino, vol. 7, Chap. 5, 267-283.
Plow et al., Inhibitions of fibrinogen binding to human platelets by the tetrapeptide glycyl-L-prolyl-L-arginyl-L-proline, Proc.Natl.Acad.Sci., vol. 79, pp. 3711-3715 (Jun. 1982).
Ginsberg et al., Inhibition of Fibronectin Binding to Platelets by Proteolytic Fragments and Synthetic Peptides Which Support Fibroblast, J.Bio.Chem., vol. 260, No. 7, pp. 3931-3936 (Apr. 10, 1985).
Haverstick et al., Inhibition of Platelet Adhesion to Fibronectin, Fibrinogen, and von Willebrand Factor Substrates by a Synthetic Tetrapeptide Derived From the Cell-Binding Domain of Fibronectin, Blood, vol. 66, No. 4, pp. 946-952 (Oct. 1985).
Gartner et al., The Tetrapeptide Analogue of the Cell Attachment Site of Fibronectin Inhibits Platelet Aggregation and Fibrinogen Binding to Activated Platelets, J.Bio.Chem., vol. 260, No. 22, pp. 11891-11894 (Oct. 5, 1985).
Plow et al., The Effect of Arg-Gly-Asp-containing peptides on fibrinogen and on Willebrand factor binding to platelets, Natl.Acad.Sci., vol. 82, pp. 8057-8061 (Dec. 1985).
Ruoslahti et al., Arg-Gly-Asp: A Versatile Cell Recognition Signal, Cell, vol. 44, pp. 517-518 (Feb. 28, 1986).
Ruggeri et al., Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platetets, Proc.Natl.Acad.Sci., vol. 83, pp. 5708-5712 (Aug. 1986).
Czekaj Mark
Gardner Charles J.
Klein Scott I.
Molino Bruce F.
Lukton David
Martin Michael B.
Parker III Raymond S.
Rhone-Poulenc Rorer Pharmaceuticals Inc.
Savitzky Martin F.
LandOfFree
Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1882778